Previous studies also support dupilumab treatment of atopic dermatitis in non-STAT3-related-IEI, such as DOCK8 deficiency (40), CARD11-associated atopy with dominant interference of NF-kB signaling (CADINS) (41), Wiskott-Aldrich Syndrome (42), common variable immune deficiency (CVID) (43), TTC7A-associated combined immunodeficiency (44), and X-linked agammaglobulinemia (45–47). Here, NFKB1 is linked to atopic eczema.